CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
ixabepilonedrug
Likely dose
Ixabepilone IV (specific dose not stated in protocol)AI-extracted
Key inclusion· 5
  • ✓Histologically confirmed ovarian epithelial cancer or primary peritoneal cancer
  • ✓Recurrent or persistent disease that is platinum AND taxane-resistant or refractory (progressed during therapy or refractory within 6 months)
  • ✓Measurable disease: ≥20 mm by conventional techniques or ≥10 mm by spiral CT scan
  • ✓GOG performance status 0-2
Key exclusion· 8
  • ✕No active brain metastases
  • ✕No sensory or motor neuropathy >grade 1
  • ✕No prior ixabepilone
  • ✕No other prior cytotoxic chemotherapy for recurrent or persistent disease, including treatment with initial regimen

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00025155
NCT00025155Phase 2Completed
CompareCT.gov

A Phase II Evaluation of Epothilone-B BMS 247550 (NSC # 710428) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or Primary Peritoneal Cancer

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Jul 24, 2019

In Brief

A Phase 2 clinical trial evaluating ixabepilone for Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer. Completed, enrolled 51 participants across 1 site.

Detailed Summary

Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
CountriesUnited States
CollaboratorsGynecologic Oncology Group

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJul 1, 2002
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 23.4 years ago

Interventions

ixabepilonedrug

Given IV